LATEST NEWS Nov 17, 2021 — ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors See the Press Release Close NEWS CONTACT US CAREERS GET E-MAIL ALERTS SEARCH Home About Us Our Products Our Pipeline Immunotechnology Plasma & IVIG Medical Affairs Investors Groundbreaking Immunotechnology, One Connection at a Time. ADMA Biologics is an end-to-end commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty plasma-derived products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection. Our devotion to these underserved populations fuels us, and our hands-on approach to production and development sets us apart. View Our Latest Corporate Presentation Discover ADMA Biologics Patented Immunotechnology* DESIGNED FOR THE IMMUNOCOMPROMISED We manufacture, develop and commercialize specialized, targeted, plasma-derived therapeutics to extend and enhance the lives of individuals who are naturally or medically immunocompromised at risk for certain infections. Screen and identify high-titer donors Hyperimmune donors with high-titer antibodies to select pathogens are identified. Tailored compositions Tailored plasma pools are derived from a unique blend of normal source plasma and plasma obtained from the selected donors. Proprietary testing A proprietary microneutralization assay quantitatively measures titer levels of neutralizing RSV antibodies in plasma donor samples. Learn more about ADMA Biologics *The following patents are applied to ASCENIV™ (immune globulin intravenous, human – slra): 9,107,906 composition 9,714,283 use 9,815,886 methods expiration 2035 Poised for Growth Beyond our present focus on the clinical advancement of ASCENIV™ and the expansion of our plasma facilities, we are considering a number of additional opportunities for growth: Evaluating strategies for potential manufacturing capacity expansion. Exploring additional clinical research and commercial opportunities to address unmet needs for immunocompromised patients. Developing additional plasma-derived products through direct R&D and potential licensing opportunities. These follow-on products may include infectious disease specific intravenous immune globulin (IVIG) product candidates targeting immunocompromised patients as well as transplant patients. ADMA Biologics offers a full suite of CDMO and CMO partnering opportunities. More For Investors Latest Stock Price $1.50 % Change 6.38% Day High $1.51 Day Low $1.37 Open $1.4042 Vol. 1.24m 52 Wk. High $3.1105 52 Wk. Low $1.01 Mkt. Cap $293.72m Symbol ADMA Exchange Nasdaq Investor Relations Fiscal Year 2020 Report Download Report Our Diversity Makes Us Stronger The members of ADMA Biologics' management team come from different disciplines and professional backgrounds, we share a common passion and desire to drive goals that improve the lives of patients. Meet the ADMA Team Latest News & Alerts ADMA Biologics Senior Vice President of Plasma Services Cyndi Tolman Elected to PPTA Source Board of Directors NOV 17, 2021 • 7:00 AM EST Read More ADMA Biologics Advances Plasma Collection Center Expansion Plans with Opening of New Facility in Myrtle Beach, SC NOV 16, 2021 • 7:00 AM EST Read More ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments NOV 10, 2021 • 4:01 PM EST Read More All News & Alerts About Us Our Products Our Pipeline Inmunotechnology Plasma & IVIG Medical Affairs Investors Privacy Policy Disclaimer Sitemap Contact Us Connect with Us Email Alerts RSS © Copyright 2021 ADMA Biologics, Inc. Ramsey, NJ Offices 201-478-5552 Boca Raton, FL Offices 561-989-5800 info@admabio.com 2020 INNOVATOR AWARD NAMED 2019 COMPANY OF THE YEAR Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.